CNO Financial Group, Inc. Q3 FY2026 earnings call

• Financial Strength & Efficiency: Operating earnings per diluted share increased 47% year-over-year to $1.90. The expense ratio improved by 50 basis points to 18.5%, reflecting strong operating leverage from sustained sales growth.
• Distribution Model: The 'last mile' captive agent model remains a core competitive moat. Producing agent counts grew 4% in the Consumer division and 6% in the Worksite division, marking consecutive quarters of growth.
• Medicare Market Dynamics: A secular shift from Medicare Advantage to Medicare Supplement is accelerating due to carrier exits and benefit reductions in the MA market. C&O’s dual offering allows agents to guide customers through this disruption, driving a 20% increase in total Medicare policies sold.
• Investment Performance: Net investment income grew 13%, with new money yields exceeding 6% for 15 consecutive quarters. Unallocated net investment income outperformed estimates by approximately 50 basis points ($12 million), though management notes this level is not sustainable long-term.
• Bermuda Reinsurance Strategy: The third reinsurance treaty transferred approximately $270 million in U.S. statutory graded benefit life reserves to the Bermuda affiliate. This diversifies liabilities and optimizes capital deployment, with further optimization planned for 2027.
• Capital Return: The company returned $77 million to shareholders during the quarter, including $60 million in share repurchases, contributing to a 4% reduction in weighted average diluted shares outstanding.

The company operates two primary segments: Consumer and Worksite. The Consumer Division reported total Life and Health Net Amounts Put (NAP) down year-over-year, driven by a strong prior year comparison; however, career field agent NAP grew 13%, and Medicare Supplement NAP surged 41% (up >60% over 12 months). Annuity collected premiums rose 9% to $514 million, and brokerage client assets reached a record high of nearly $20 billion. The Worksite Division achieved its 18th consecutive quarter of sales growth, with Life and Health NAP up 18% and producing agent count reaching a record level, up 6%. Specific product highlights included Life NAP up 59% and Hospital Indemnity/Accident up 16%.

• Operating EPS: Raised full-year 2026 guidance to $5.05–$5.15 per diluted share, representing a 9% increase at the midpoint from prior estimates.
• Expense Ratio: Revised downward to 18.6%–18.8% (from 18.8%–19.0%), reflecting continued operating leverage.
• Tax Rate: Reduced operating effective tax rate estimate to approximately 20.5% (from 21.5%).
• Free Cash Flow: Established a tighter guidance range of $220 million–$240 million for the full year.
• Fee Income: Expected full-year fee income of approximately $25 million, driven by the shift toward Medicare Supplement products.
• ROE Trajectory: Confirmed that 2026 operating return on equity will exceed the 12% target, with plans to establish new long-term targets in February 2027 aiming for top-quartile peer performance.

• Macroeconomic Sensitivity: While management asserts demand for middle-income protection products is resilient against inflation or interest rate pressures, there remains potential for marginal impact on consumers close to the decision threshold.
• Medicare Advantage Disruption: The exit of carriers from Medicare Advantage creates operational complexity but also opportunity; failure to effectively capture these displaced members could limit growth.
• Morbidity Trends: Unfavorable morbidity trends in Medicare Supplement partially offset block growth, requiring careful reserve management.
• Investment Yield Sustainability: Recent outperformance in unallocated net investment income (driven by alternative investments) is acknowledged as non-recurring, posing a risk if future yields revert to historical averages.
• Regulatory Risk: Continued expansion of the Bermuda operations requires ongoing regulatory approval and cooperation from both U.S. and Bermuda authorities.

Q: Analyst asked about the rationale behind the free cash flow guidance range and how the $270M reinsurance transfer impacts capital availability. / A: CFO explained that FCF balances organic growth funding, investment optimization, and shareholder returns. The third reinsurance treaty solved for excess capital built up in Bermuda over three years, positively impacting FCF. Future capital optimization in Bermuda remains a 2027 focus area subject to regulatory approval.

Q: Analyst inquired whether economic pressures (gas prices, rates) would impact production in Q4/2027 and if staffing/advertising needs to change to capitalize on Medicare Advantage disruptions. / A: CEO stated demand remains robust because middle-income consumers lack credible alternatives for coverage gaps. The shift from MA to Med Supp benefits C&O’s advisory-led model; dislocations drive consumers to seek advice rather than just price-shop, reinforcing their competitive advantage without needing significant new marketing spend.

Q: Analyst questioned why more traditional life business isn't being ceded to Bermuda given potential efficiencies. / A: Management clarified that the current block (~600,000 policies) is optimal for diversification. They are not pressured by regulators to transfer more. The strategy focuses on optimizing assets/liabilities within the existing diversified structure rather than maximizing volume transfers.

Q: Analyst sought details on assumption review impacts on GAAP vs. Statutory earnings and specific drivers of favorable run-rates in annuities/med sup. / A: Chief Actuary noted assumption updates created favorable GAAP unlocks (reserve releases) due to lower expected GLWB utilization and higher surrenders. Statutory earnings remain largely locked-in at issue, so GAAP improvements do not directly translate to Statutory earnings, which face strain from new business growth.